Stoke Therapeutics Inc
NASDAQ:STOK

Watchlist Manager
Stoke Therapeutics Inc Logo
Stoke Therapeutics Inc
NASDAQ:STOK
Watchlist
Price: 8.6 USD 6.04% Market Closed
Market Cap: 455.5m USD

Net Margin
Stoke Therapeutics Inc

-629.9%
Current
-1 034%
Average
-7%
Industry

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-629.9%
=
Net Income
-105.5m
/
Revenue
16.7m

Net Margin Across Competitors

Country Company Market Cap Net
Margin
US
Stoke Therapeutics Inc
NASDAQ:STOK
455.3m USD
-630%
FR
Pharnext SCA
OTC:PNEXF
6T USD
-21 040%
US
Abbvie Inc
NYSE:ABBV
373.8B USD
8%
US
Amgen Inc
NASDAQ:AMGN
168.4B USD
12%
US
Gilead Sciences Inc
NASDAQ:GILD
138.9B USD
2%
US
Vertex Pharmaceuticals Inc
NASDAQ:VRTX
129.7B USD
-5%
US
Epizyme Inc
F:EPE
94.1B EUR
-392%
AU
CSL Ltd
ASX:CSL
121.1B AUD
18%
US
Regeneron Pharmaceuticals Inc
NASDAQ:REGN
73.1B USD
31%
US
Seagen Inc
F:SGT
39.3B EUR
-33%
NL
argenx SE
XBRU:ARGX
32.9B EUR
38%

Stoke Therapeutics Inc
Glance View

Market Cap
455.3m USD
Industry
Biotechnology

Stoke Therapeutics, Inc. is a biotechnology company, which engages in the research and development of treatments for genetic diseases. The company is headquartered in Bedford, Massachusetts and currently employs 102 full-time employees. The company went IPO on 2019-06-19. The company focuses to treat the underlying causes of severe genetic diseases by upregulating protein expression. The company is developing antisense oligonucleotide (ASO) medicines that target ribonucleic acid (RNA) and modulate precursor-messenger RNA (pre-mRNA) splicing to upregulate protein expression where needed and with appropriate specificity to near normal levels. The company focuses to develop the precision medicine platform to target the underlying cause of a spectrum of genetic diseases in which the patient has healthy copy of a gene and mutated copy that fails to produce a protein essential to health. The company utilizes its technology platform, Targeted Augmentation of Nuclear Gene Output (TANGO) to design ASOs to upregulate the expression of protein by individual genes in a patient. Its product candidate, STK-001, is offered to treat Dravet syndrome. Its research platform is designed to address protein deficiency.

STOK Intrinsic Value
5.36 USD
Overvaluation 38%
Intrinsic Value
Price
What is Net Margin?

Net Margin measures how much net income is generated as a percentage of revenues received. It helps investors assess if a company's management is generating enough profit from its sales and whether operating costs and overhead costs are being contained.

Net Margin
-629.9%
=
Net Income
-105.5m
/
Revenue
16.7m
What is the Net Margin of Stoke Therapeutics Inc?

Based on Stoke Therapeutics Inc's most recent financial statements, the company has Net Margin of -629.9%.

Back to Top